BEAM

Beam Therapeutics

Halal Rating :
Comfortable
Last Price $23.44 Last updated:
Market Cap $2.2b
7D Change -8.22%
1 Year Change -5.33%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Biological Products
  • Except Diagnostic Substances
Exchange NASDAQ
Next Earnings Date Nov. 6, 2024

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines through its proprietary base editing technology. The company aims to treat serious diseases by precisely targeting and editing the genes associated with these conditions. Their technology allows them to make highly specific edits to DNA bases without cutting the DNA strand, potentially offering more precise genetic modifications with fewer unwanted effects than traditional gene editing approaches.

The company is currently in the research and development phase, working on various programs targeting conditions in areas including hematology, oncology, and genetic diseases. As a pre-commercial stage company, Beam's primary activities involve research, development, and advancing their therapeutic candidates through clinical trials.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $14.27m $108.65m - $-12127000.0 0.00% 11.16%
June 30, 2024 $11.77m $102.48m - $-14190000.0 0.00% 13.85%
March 31, 2024 $7.41m $99.69m - $-11849000.0 0.00% 11.89%

Company Impact

Help us evaluate Beam Therapeutics's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates